OUTCOMES OF PATIENTS WITH WORSENING ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) DESPITE DAILY THERAPEUTIC PLASMA EXCHANGE IN THE PHASE 3 HERCULES TRIAL

• M. Scully,
• J.L. Rubia,
• F. Peyvandi,
• S. Cataland,
• P. Coppo,
• J.A.K. Hovinga,
• P. Knoebl,
• K. Pavenski,
• F. Callewaert,
• J.M.M. Edou,
• R.P. Sousa

Affiliations

M. Scully

Cardiometabolic Programme, NIHR UCLH/UCL BRC, Department of Haematology, University College London Hospital, London, United Kingdom

J.L. Rubia

Hematology Department, Internal Medicine, School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain; Hospital Doctor Peset, Valencia, Spain

F. Peyvandi

Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy

S. Cataland

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, United States

P. Coppo

Department of Hematology, Reference Center for Thrombotic Microangiopathies (CNR-MAT), Saint-Antoine University Hospital, AP-HP, Paris, France

J.A.K. Hovinga

Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

P. Knoebl

Division of Hematology and Hemostasis, Department of Medicine 1, Medical University of Vienna, Wien, Austria

K. Pavenski

Departments of Medicine and Laboratory Medicine, St. Michael's Hospital, University of Toronto, Toronto, Canada

F. Callewaert

Sanofi, Diegem, Belgium

J.M.M. Edou

Sanofi, Zwijnaarde, Belgium

R.P. Sousa

Sanofi, Lisbon, Portugal